Exploration of structure-based on Imidazole core as antibacterial agents

Current Topics in Medicinal Chemistry

Volumn 13, Issue 24, 2013, Pages 3118-3130

  Duan, Yong Tao ^a   Wang, Zhong Chang ^a   Sang, Ya Li ^a   Tao, Xiang Xiang ^a   Zhu, Hai Liang ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Antibacterial activity; Antibacterial agents; Docking; Imidazole; Kinase inhibitor; QSAR; Resistance to antibiotics; Structure activity relationship

Indexed keywords

ANTIINFECTIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BETA LACTAMASE INHIBITOR; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; FATTY ACID SYNTHASE INHIBITOR; GLUTAMATE RACEMASE INHIBITOR; GYRASE INHIBITOR; IMIDAZOLE DERIVATIVE; ISOMERASE INHIBITOR; UNCLASSIFIED DRUG; UREASE INHIBITOR;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACILLUS SUBTILIS; CHEMICAL STRUCTURE; ESCHERICHIA COLI; HELICOBACTER PYLORI; HUMAN; NONHUMAN; PROTEUS VULGARIS; PSEUDOMONAS AERUGINOSA; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; STAPHYLOCOCCUS AUREUS;

ACETYLTRANSFERASES; AMINO ACID ISOMERASES; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENZYME INHIBITORS; ESCHERICHIA COLI PROTEINS; FATTY ACID SYNTHASE, TYPE II; HELICOBACTER PYLORI; IMIDAZOLES; MICROBIAL SENSITIVITY TESTS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; TOPOISOMERASE II INHIBITORS; UREASE;

EID: 84890907215     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/15680266113136660222     Document Type: Review

References (117)

1. Varshney, V.; Mishra, N.N.; Shukla, P.K.; Sahu, D.P. Synthesis of nitroimidazole derived oxazolidinones as antibacterial agents. Eur. J. Med. Chem., 2010, 45(2), 661-666.
2. Monaghan, R.L.; Barrett, J.F. Antibacterial drug discovery-then, now and the genomics future. Biochem. Pharmacol., 2006, 71(7), 901-909.
3. Gastmeier, P.; Sohr, D.; Geffers, C.; Behnke, M.; Daschner, F.; Ruden, H. Mortality risk factors with nosocomial Staphylococcus aureus infections in intensive care units: results from the German Nosocomial Infection Surveillance System (KISS). Infection, 2005, 33(2), 50-55.
4. Bhat, A.R.; Tazeem; Azam, A.; Choi, I.; Athar, F. 3-(1,3,4-Thiadiazole-2-yl)quinoline derivatives: synthesis, characterization and anti-microbial activity. Eur. J. Med. Chem., 2011, 46(7), 3158-3166.
5. Zhan, P.; Liu, X.; Cao, Y.; Wang, Y.; Pannecouque, C.; De Clercq, E. 1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18 (20), 5368-5371.
6. Otvos, L.; Wade, J.D.; Lin, F.; Condie, B.A.; Hanrieder, J.; Hoffmann, R. Designer antibacterial peptides kill fluoroquinolone-resistant clinical isolates. J. Med. Chem., 2005, 48(16), 5349-5359.
7. Felmingham, D.; Reinert, R.R.; Hirakata, Y.; Rodloff, A. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin. J. Antimicrob. Chemother., 2002, 50(suppl 2), 25-37.
8. Doern, G.V.; Heilmann, K.P.; Huynh, H.K.; Rhomberg, P.R.; Coffman, S.L.; Brueggemann, A.B. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob. Agents Chemother., 2001, 45(6), 1721-1729.
9. Li, Z.-L.; Li, Q.-S.; Zhang, H.-J.; Hu, Y.; Zhu, D.-D.; Zhu, H.-L. Design, synthesis and biological evaluation of urea derivatives from o-hydroxybenzylamines and phenylisocyanate as potential FabH inhibitors. Bioorg. Med. Chem., 2011, 19(15), 4413-4420.
10. Yendapally, R.; Hurdle, J.G.; Carson, E.I.; Lee, R.B.; Lee, R.E. N-substituted 3-acetyltetramic acid derivatives as antibacterial agents. J. Med. Chem., 2008, 5 (5), 1487-1491.
11. Li, H.-Q.; Lv, P.-C.; Shi, L.; Zhu, H.-L. Structure-based Discovery of Novel Antibacterials. Anti-Infective Agents in Med. Chem. (Formerly Curr. Med. Chem.-Anti-Infective Agents), 2010, 9(4), 168-179.
12. Ashish, B.; Pandeya, S. Various approaches for synthesis of imidazole derivatives. IJRAP, 2011, 2(4), 1124-1129.
13. Kumar, J.R. Review of imidazole heterocyclic ring containing compounds with their biological activity. Hypertension, 2010, 1(3), 167-177.
14. Khabnadideh, S.; Rezaei, Z.; Ghasemi, Y.; Montazeri-Najafabady, N. Antibacterial activity of some new azole compounds. Anti-Infective Agents, 2012, 10(1), 26-33.
15. Atia, A.J.K. Synthesis and antibacterial activities of new metronidazole and imidazole derivatives. Molecules, 2009, 14(7), 2431-2446.
16. Liu, Y.-T.; Sun, X.-M.; Yin, D.-W.; Yuan, F. Syntheses and biological activity of chalcones-imidazole derivatives. Res. on Chem. Intermed., 2013,3(39), 1-12.
17. Foster, E.J.; Lavigueur, C.; Ke, Y. C.; Williams, V.E. Self-assembly of hydrogen-bonded molecules: discotic and elliptical mesogens. J. Mater. Chem., 2005, 15(37), 4062-4068.
18. Nguyen, H.T.; Destrade, C.; Malthécte, J. Phasmids and polycatenar mesogens. Advanced Materials, 1997, 9(5), 375-388.
19. Luca, L.D. Naturally occurring and synthetic imidazoles: Their chemistry and their biological activities. Curr. Med. Chem., 2006, 13(1), 1-23.
20. Suzuki, F.; Kuroda, T.; Tamura, T.; Sato, S.; Ohmori, K.; Ichikawa, S. New antiinflammatory agents. 2. 5-Phenyl-3H-imidazo [4, 5- c][1, 8] naphthyridin-4 (5H)-ones: a new class of nonsteroidal antiinflammatory agents with potent activity like glucocorticoids. J. Med. Chem., 1992, 35(15), 2863-2870.
21. Pinza, M.; Farina, C.; Cerri, A.; Pfeiffer, U.; Riccaboni, M.T.; Banfi, S.; Biagetti, R.; Pozzi, O.; Magnani, M.; Dorigotti, L. Synthesis and pharmacological activity of a series of dihydro-1H-pyrrolo [1, 2-a] imidazole-2, 5 (3H, 6H)-diones, a novel class of potent cognition enhancers. J. Med. Chem., 1993, 36(26), 4214-4220.
22. Pandey, J.; Tiwari, V.K.; Verma, S.S.; Chaturvedi, V.; Bhatnagar, S.; Sinha, S.; Gaikwad, A.; Tripathi, R.P. Synthesis and antitubercular screening of imidazole derivatives. Eur. J. Med. Chem., 2009, 44(8), 3350-3355.
23. Riché, F.; Du Moulinet d'Hardemare, A.; Sépe, S.; Riou, L.; Fagret, D.; Vidal, M. Nitroimidazoles and hypoxia imaging: synthesis of three technetium-99m complexes bearing a nitroimidazole group: biological results. Bioorg. Med. Chem. Lett., 2001, 11(1), 71-74.
24. Miyachi, H.; Kiyota, H.; Segawa, M. Novel imidazole derivatives with subtype-selective antimuscarinic activity. Bioorg. Med. Chem. Lett., 1998, 8(16), 2163-2168.
25. Papadopoulou, M.V.; Trunz, B.B.; Bloomer, W.D.; McKenzie, C.; Wilkinson, S.R.; Prasittichai, C.; Brun, R.; Kaiser, M.; Torreele, E. Novel 3-Nitro-1 H-1, 2, 4-triazole-Based Aliphatic and Aromatic Amines as Anti-Chagasic Agents. J. Med. Chem., 2011, 54(23), 8214-8223.
26. Reigan, P.; Edwards, P.N.; Gbaj, A.; Cole, C.; Barry, S.T.; Page, K.M.; Ashton, S.E.; Luke, R.W.; Douglas, K.T.; Stratford, I.J. Aminoimidazolylmethyluracil analogues as potent inhibitors of thymidine phosphorylase and their bioreductive nitroimidazolyl prodrugs. J. Med. Chem., 2005, 48(2), 392-402.
27. Löfmark, S.; Fang, H.; Hedberg, M.; Edlund, C. Inducible metronidazole resistance and nim genes in clinical Bacteroides fragilis group isolates. Antimicrob. Agents Chemother., 2005, 49(3), 1253-1256.
28. Todar, K. Todar's online textbook of bacteriology. University of Wisconsin-Madison Department of Bacteriology, 2006.
29. Chu, D.T.; Plattner, J.J.; Katz, L. New directions in antibacterial research. J. Med. Chem., 1996, 39(20), 3853-3874.
30. Overbye, K.M.; Barrett, J.F. Antibiotics: where did we go wrong. Drug Discov. Today, 2005, 10(1), 45-52.
31. Levy, S.B. The antibiotic paradox: how the misuse of antibiotics destroys their curative powers. Da Capo Press, 2002.
32. Chroma, M.; Kolar, M. Genetic methods for detection of antibiotic resistance: focus on extended-spectrum P-lactamases. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech. Repub., 2010, 154(4), 289-296.
33. Weile, J.; Knabbe, C. Current applications and future trends of molecular diagnostics in clinical bacteriology. Analy. Bioanaly. Chem., 2009, 394(3), 731-742.
34. Srinivasan, V.; Nam, H.; Nguyen, L.; Tamilselvam, B.; Murinda, S.; Oliver, S. Prevalence of antimicrobial resistance genes in Listeria monocytogenes isolated from dairy farms. Foodbourne Path. & Dis., 2005, 2(3), 201-211.
35. Wright, G.D. Bacterial resistance to antibiotics: enzymatic degradation and modification. Adv. Drug Deliv. Rev., 2005, 57(10), 1451-1470.
36. Lambert, P.A. Bacterial resistance to antibiotics: modified target sites. Advanced drug delivery reviews, 2005, 57(10), 1471-1485.
37. Kumar, A.; Schweizer, H.P. Bacterial resistance to antibiotics: active efflux and reduced uptake. Adv. Drug Deliv. Rev., 2005, 57(10), 1486-1513.
38. Andersson, D.I.; Levin, B.R. The biological cost of antibiotic resistance. Curr. Opin. Microbiol, 1999, 2(5), 489-493.
39. Zhang, Y.Y.; Zhou, C.H. Synthesis and activities of naphthalimide azoles as a new type of antibacterial and antifungal agents. Bioorg. Med. Chem. Lett, 2011, 21(14), 4349-4352.
40. Ramachandran, R.; Rani, M.; Senthan, S.; Jeong, Y.T.; Kabilan, S. Synthesis, spectral, crystal structure and in vitro antimicrobial evaluation of imidazole/benzotriazole substituted piperidin-4-one derivatives. Eur. J. Med. Chem., 2011, 46(5), 1926-1934.
41. Zhang, F.-F.; Gan, L.L.; Zhou, C.H. Synthesis, antibacterial and antifungal activities of some carbazole derivatives. Bioorg. Med. Chem. Lett., 2010, 20(6), 1881-1884.
42. Sharma, D.; Narasimhan, B.; Kumar, P.; Judge, V.; Narang, R.; De Clercq, E.; Balzarini, J. Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives. Eur. J. Med. Chem., 2009, 44(6), 2347-2353.
43. Ross, W.J.; Jamieson, W.B.; McCowen, M.C. Antiparasitic nitroimidazoles. 1. 2-Styryl-5-nitroimidazoles. J. Med. Chem., 1972, 15(10), 1035-1040.
44. Basarab, G.S.; Hill, P.; Eyermann, C.J.; Gowravaram, M.; Käck, H.; Osimoni, E. Design of inhibitors of Helicobacter pylori glutamate racemase as selective antibacterial agents: Incorporation of imidazoles onto a core pyrazolopyrimidinedione scaffold to improve bioavailabilty. Bioorg. Med. Chem. Lett, 2012, 22(17), 5600-5607.
45. Sharma, P.; Rane, N.; Gurram, V. Synthesis and QSAR studies of pyrimido [4, 5- d] pyrimidine-2, 5-dione derivatives as potential antimicrobial agents. Bioorg. Med. Chem. Lett, 2004, 14(16), 4185-4190.
46. Wang, Z.C.; Duan, Y.T.; Qin, Y.J.; Wang, P.F.; Luo, Y.; Wen, Q.; Yang, Y.A.; Sun, J.; Hu, Y.; Sang, Y.L.; Zhu, H.L. Potentiating 1-(2-hydroxypropyl)-2-styryl-5-nitroimidazole derivatives against antibacterial agents: Design, synthesis and biology analysis. Eur. J. Med. Chem., 2013, 65(2013), 456-463.
47. Ghaemy, M.; Aghakhani, B.; Taghavi, M.; Nasab, S.M.A.; Mohseni, M. Synthesis and characterization of new imidazole and fluorene-bisphenol based polyamides: Thermal, photophysical and antibacterial properties. Reactive Funct. Polym., 2013, 73(3), 555-563.
48. Li, Y.; Luo, Y.; Hu, Y.; Zhu, D.D.; Zhang, S.; Liu, Z.J.; Gong, H.B.; Zhu, H.L. Design, synthesis and antimicrobial activities of nitroimidazole derivatives containing 1,3,4-oxadiazole scaffold as FabH inhibitors. Bioorg. Med. Chem., 2012, 20(14), 4316-4322.
49. Desai, N.C.; Joshi, V.V.; Rajpara, K.M.; Makwana, A.H. A new synthetic approach and in vitro antimicrobial evaluation of novel imidazole incorporated 4-thiazolidinone motifs. Arabian Journal of Chemistry, 2012, http://dx.doi.org/10.1016/j.arabjc.2012.10.020.
50. Vijesh, A.M.; Isloor, A.M.; Telkar, S.; Peethambar, S.K.; Rai, S.; Isloor, N. Synthesis, characterization and antimicrobial studies of some new pyrazole incorporated imidazole derivatives. Eur. J. Med. Chem., 2011, 46(8), 3531-3536.
51. Abdel-Wahab, B.F.; Awad, G.E.; Badria, F.A. Synthesis, antimicrobial, antioxidant, anti-hemolytic and cytotoxic evaluation of new imidazole-based heterocycles. Eur. J. Med. Chem., 2011, 46(5), 1505-1511.
52. Mao, W.J.; Lv, P.C; Shi, L.; Li, H.Q.; Zhu, H.L. Synthesis, molecular docking and biological evaluation of metronidazole derivatives as potent Helicobacter pylori urease inhibitors. Bioorg. Med. Chem., 2009, 17(21), 7531-7536.
53. Khan, M.S.; Siddiqui, S.A.; Siddiqui, M.S.; Goswami, U.; Srinivasan, K.V.; Khan, M.I. Antibacterial activity of synthesized 2,4,5-trisubstituted imidazole derivatives. Chem. Biol. Drug Des., 2008, 72(3), 197-204.
54. Khalafi-Nezhad, A.; Soltani Rad, M.N.; Mohabatkar, H.; Asrari, Z.; Hemmateenejad, B. Design, synthesis, antibacterial and QSAR studies of benzimidazole and imidazole chloroaryloxyalkyl derivatives. Bioorg. Med. Chem., 2005,13(6), 1931-1938.
55. Bahnous, M.; Bouraiou, A.; Chelghoum, M.; Bouacida, S.; Roisnel, T.; Smati, F.; Bentchouala, C; Gros, P.C.; Belfaitah, A. Synthesis, crystal structure and antibacterial activity of new highly functionalized ionic compounds based on the imidazole nucleus. Bioorg. Med. Chem. Lett., 2013, 23(5), 1274-1278.
56. Desai, N.C.; Joshi, V.V.; Rajpara, K.M.; Vaghani, H.V.; Satodiya, H.M. Microwave-assisted synthesis and antimicrobial screening of new imidazole derivatives bearing 4-thiazolidinone nucleus. Med. Chem. Res., 2012, 22(4), 1893-1908.
57. Desai, N.C.; Maheta, A.S.; Rajpara, K.M.; Joshi, V.V.; Vaghani, H.V.; Satodiya, H.M. Green synthesis of novel quinoline based imidazole derivatives and evaluation of their antimicrobial activity. J. Saudi Chem. Soci., 2011, http://dx.doi.org/10.1016/jjscs. 2011.11.021.
58. Jain, A.K.; Ravichandran, V.; Sisodiya, M.; Agrawal, R. Synthesis and antibacterial evaluation of 2-substituted-4, 5-diphenyl-N-alkyl imidazole derivatives. Asian Pac. J. Trop. Med., 2010, 3(6), 471-474.
59. Atia, A.J. Synthesis and antibacterial activities of new metronidazole and imidazole derivatives. Molecules, 2009, 14(7), 2431-2446.
60. Nagarapu, L.; Satyender, A.; Rajashaker, B.; Srinivas, K.; Rupa rani, P.; Radhika, K.; Subhashini, G. Synthesis and antimicrobial activity of novel C-linked imidazole glycoconjugates. Bioorg. Med. Chem. Lett., 2008,18(3), 1167-1171.
61. Tatsuta, K.; Miura, S.; Ohta, S.; Gunji, H. Total syntheses of de-branched nagstatin and its analogs having glycosidase inhibiting activities. Tetrahedron Lett., 1995,36(7), 1085-1088.
62. Aoyama, T.; Naganawa, H.; Muroka, Y.; Nakamura, H.; Aoyagi, T.; Takeuchi, T.; Iitaka, Y. Benastatins A and B, new inhibitors of glutathione S-transferase, produced by Streptomyces sp. MI384-DF12. II: Structure determination of benastatins A and B. J. Antibiot. (Tokyo), 1992,45(9), 1391-1396.
63. Aoyagi, T.; Suda, H.; Uotani, K.; Kojima, F.; Aoyama, T.; Horiguchi, K.; Hamada, M.; Takeuchi, T. Nagstatin, a new inhibitor of N-acetyl-beta-D-glucosaminidase, produced by Streptomyces amakusaensis MG846-fF3. Taxonomy, production, isolation, physico-chemical properties and biological activities. J. Antibiot., 1992,45(9), 1404-1408.
64. Zou, R.; Ayres, K.R.; Drach, J.C.; Townsend, L.B. Synthesis and Antiviral Evaluation of Certain Disubstituted Benzimidazole Ribonucleosides 1. J. Med. Chem., 1996, 39(18), 3477-3482.
65. Townsend, L.B.; Wise, D.S. The synthesis and chemistry of certain anthelmintic benzimidazoles. Parasitol. Today, 1990, 6(4), 107-112.
66. Kleemann, A.; Engel, J.; Kutscher, B.; Reichert, D. Pharmaceutical substances: syntheses, patents, applications. Thieme Stuttgart, 1999.
67. Walker, K.A.; Braemer, A.C.; Hitt, S.; Jones, R.E.; Matthews, T.R. 1-[4-(4-Chlorophenyl)-2-(2, 6-dichlorophenylthio)-n-butyl]-1H-imidazole nitrate, a new potent antifungal agent. J. Med. Chem., 1978, 21(8), 840-843.
68. Sun, X.Y.; Wu, R.; Wen, X.; Guo, L.; Zhou, C.P.; Li, J.; Quan, Z.S.; Bao, J. Synthesis and evaluation of antibacterial activity of 7-alkyloxy-4,5-dihydro-imidazo[1,2-a]quinoline derivatives. Eur. J. Med. Chem., 2013, 60(2013), 451-455.
69. Kumar, K.; Awasthi, D.; Lee, S.Y.; Cummings, J.E.; Knudson, S.E.; Slayden, R.A.; Ojima, I. Benzimidazole-based antibacterial agents against Francisella tularensis. Bioorg. Med. Chem., 2013, 21(11), 3318-3326.
70. Nath, A.R.; Reddy, M.S. Design, Synthesis, Antibacterial and Antifungal Activity of Novel 2-[(E)-2-aryl-1-ethenyl]-3-(2- sulfanyl-1H-benzo [d] imidazole-5-yl)-3, 4-dihydro-4-quinolinones. J. Chem., 2012,9(3), 1481-1489.
71. Sandanayaka, V.P.; Prashad, A.S. Resistance to beta-lactam antibiotics: structure and mechanism based design of beta-lactamase inhibitors. Curr. Med. Chem., 2002, 9(12), 1145-1165.
72. Micetich, R.; Salama, S.; Maiti, S.; Reddy, A.; Singh, R. Beta-Lactamases and their Inhibitors: An Update. Curr. Med. Chem.-Anti-Infective Agents, 2002, 1(3), 193-213.
73. Du, W.; Brown, J.R.; Sylvester, D.R.; Huang, J.; Chalker, A.F.; So, C.Y.; Holmes, D.J.; Payne, D.J.; Wallis, N.G. Two active forms of UDP-N-acetylglucosamine enolpyruvyl transferase in gram-positive bacteria. J. Bacteriol, 2000, 182(15), 4146-4152.
74. Bush, K.; Jacoby, G.A.; Medeiros, A.A. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother., 1995,39(6), 1211.
75. Venkatesan, A.M.; Agarwal, A.; Abe, T.; Ushirogochi, H.; Yamamura, I.; Kumagai, T.; Petersen, P.J.; Weiss, W.J.; Lenoy, E.; Yang, Y.; Shlaes, D.M.; Ryan, J.L.; Mansour, T.S. Novel imidazole substituted 6-methylidene-penems as broad-spectrum beta-lactamase inhibitors. Bioorg. Med. Chem., 2004, 12(22), 5807-5817.
76. Venkatesan, A.M.; Agarwal, A.; Abe, T.; Ushirogochi, H.; Ado, M.; Tsuyoshi, T.; Dos Santos, O.; Li, Z.; Francisco, G.; Lin, Y.I.; Petersen, P.J.; Yang, Y.; Weiss, W.J.; Shlaes, D.M.; Mansour, T.S. 5,5,6-Fused tricycles bearing imidazole and pyrazole 6-methylidene penems as broad-spectrum inhibitors of beta-lactamases. Bioorg. Med. Chem., 2008, 16(4), 1890-1902.
77. Price, A.C.; Zhang, Y.M.; Rock, CO.; White, S.W. Structure of β- ketoacyl-[acyl carrier protein] reductase from Escherichia coli: negative cooperativity and its structural basis. Biochemistry, 2001,40(43), 12772-12781.
78. Campbell, J.W.; Cronan Jr, J.E. Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery. Annual Reviews in Microbiology, 2001, 55(1), 305-332.
79. Choi, K.-H.; Heath, R.J.; Rock, CO. P-Ketoacyl-acyl carrier protein synthase III (FabH) is a determining factor in branched-chain fatty acid biosynthesis. J. Bacteriol, 2000,182(2), 365-370.
80. Khandekar, S.S.; Daines, R.A.; Lonsdale, J.T. Bacterial beta-ketoacyl-acyl carrier protein synthases as targets for antibacterial agents. Current Protein and Peptide Science, 2003, 4(1), 21-29.
81. Heath, R.J.; Rock, CO. The Claisen condensation in biology. Nat. Prod. Rep., 2002, 19(5), 581-596.
82. Clough, R.; Matthis, A.; Barnum, S.; Jaworski, J. Purification and characterization of 3-ketoacyl-acyl carrier protein synthase III from spinach. A condensing enzyme utilizing acetyl-coenzyme A to initiate fatty acid synthesis. J. Biol. Chem., 1992, 267(29), 20992-20998.
83. Heath, R.J.; Rock, CO. Regulation of fatty acid elongation and initiation by acyl-acyl carrier protein in Escherichia coli. J. Biol. Chem., 1996, 271(4), 1833-1836.
84. Luo, Y.; Yang, Y.S.; Fu, J.; Zhu, H.L. Novel FabH inhibitors: a patent and article literature review (2000-2012). Expert Opin. Ther. Pat., 2012,22(11), 1325-1336.
85. Qiu, X.; Janson, C.A.; Smith, W.W.; Head, M.; Lonsdale, J.; Konstantinidis, A.K. Refined structures of P-ketoacyl-acyl carrier protein synthase III. J. Mol. Biol, 2001, 307(1), 341-356.
86. Kim, O.K.; Ohemeng, K.A. Patents on DNA gyrase inhibitors: January 1995 to March 1998. Expert Opin. Ther. Pat., 1998, 8(8), 959-969.
87. Ferrero, L.; Cameron, B.; Manse, B.; Lagneaux, D.; Crouzet, J.; Famechon, A.; Blanche, F. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol. Microbiol, 1994, 13(4), 641-653.
88. 2+ chelator, EGTA. Biochimie, 1999, 81(8), 909-913.
89. Hiraga, S.; Niki, H.; Ogura, T.; Ichinose, C; Mori, H.; Ezaki, B.; Jaffe, A. Chromosome partitioning in Escherichia coli: novel mutants producing anucleate cells. J. Bacteriol, 1989, 171(3), 1496-1505.
90. Tanitame, A.; Oyamada, Y.; Ofuji, K.; Fujimoto, M.; Iwai, N.; Hiyama, Y.; Suzuki, K.; Ito, H.; Terauchi, H.; Kawasaki, M. Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives. J. Med. Chem., 2004, 47(14), 3693-3696.
91. Jones, K.R.; Cha, J.-H.; Merrell, D.S. Who's winning the war Molecular mechanisms of antibiotic resistance in Helicobacter pylori. Curr. Drug Ther., 2008, 3(3), 190.
92. Kim, S.S.; Ruiz, V.E.; Carroll, J.D.; Moss, S.F. Helicobacter pylori in the pathogenesis of gastric cancer and gastric lymphoma. Cancer Lett., 2011, 305(2), 228-238.
93. Malfertheiner, P.; Bornschein, J.; Selgrad, M. Role of Helicobacter pylori infection in gastric cancer pathogenesis: a chance for prevention. J. Dig. Dis., 2010, 11(1), 2-11.
94. Vassiliou, S.; Grabowiecka, A.; Kosikowska, P.; Yiotakis, A.; Kafarski, P.; Berlicki, L. Design, synthesis, and evaluation of novel organophosphorus inhibitors of bacterial ureases. J. Med. Chem., 2008, 51(18), 5736-5744.
95. Reyrat, J.M.; Pelicic, V.; Papini, E.; Montecucco, C; Rappuoli, R.; Telford, J.L. Towards deciphering the Helicobacter pylori cytotoxin. Mol. Microbiol., 1999, 34(2), 197-204.
96. Khan, K.M.; Iqbal, S.; Lodhi, M.A.; Maharvi, G.M.; Ullah, Z.; Choudhary, M.I.; Rahman, A.-u.; Perveen, S. Biscoumarin: new class of urease inhibitors; economical synthesis and activity. Bioorg. Med. Chem., 2004, 12(8), 1963-1968.
97. Amtul, Z.; Rasheed, M.; Choudhary, M.I.; Rosanna, S.; Khan, K.M. Kinetics of novel competitive inhibitors of urease enzymes by a focused library of oxadiazoles/thiadiazoles and triazoles. Biochem. Biophys. Res. Commun., 2004, 319(3), 1053-1063.
98. Ahmad, V.U.; Hussain, J.; Hussain, H.; Jassbi, A.R.; Ullah, F.; Lodhi, M.A.; Yasin, A.; Choudhary, M.I. First natural urease inhibitor from Euphorbia decipiens. Chem. Pharm. Bull. (Tokyo), 2003, 51(6), 719-723.
99. Amtul, Z.; Siddiqui, R.; Choudhary, M. Chemistry and mechanism of urease inhibition. Curr. Med. Chem., 2002, 9(14), 1323-1348.
100. Van Heijenoort, J. Recent advances in the formation of the bacterial peptidoglycan monomer unit. Nat. Prod. Rep., 2001, 18(5), 503-519.
101. Glavas, S.; Tanner, M.E. Active site residues of glutamate racemase. Biochemistry, 2001, 40(21), 6199-6204.
102. Doublet, P.; van Heijenoort, J.; Mengin-Lecreulx, D. The glutamate racemase activity from Escherichia coli is regulated by peptidoglycan precursor UDP-N-acetylmuramoyl-L-alanine. Biochemistry, 1994, 33(17), 5285-5290.
103. Doublet, P.; van Heijenoort, J.; Mengin-Lecreulx, D. Identification of the Escherichia coli murI gene, which is required for the biosynthesis of D-glutamic acid, a specific component of bacterial peptidoglycan. J. Bacteriol, 1992, 174(18), 5772-5779.
104. Fisher, S.L. Glutamate racemase as a target for drug discovery. Microb. Biotechnol, 2008, 1(5), 345-360.
105. Supuran, C.T. Novel targets against Helicobacter pylori: a bioinformatic approach. Future Microbiol, 2007, 2(2), 111-114.
106. Lundqvist, T.; Fisher, S.L.; Kern, G.; Folmer, R.H.; Xue, Y.; Newton, D.T.; Keating, T.A.; Alm, R.A.; de Jonge, B.L. Exploitation of structural and regulatory diversity in glutamate racemases. Nature, 2007, 447(7146), 817-822.
107. Doig, P.; de Jonge, B.L.; Alm, R.A.; Brown, E.D.; Uria-Nickelsen, M.; Noonan, B.; Mills, S.D.; Tummino, P.; Carmel, G.; Guild, B.C. Helicobacter pylori physiology predicted from genomic comparison of two strains. Microbiol. Mol. Biol. Rev., 1999, 63(3), 675-707.
108. Basarab, G.S.; Hill, P.; Eyermann, C.J.; Gowravaram, M.; Kack, H.; Osimoni, E. Design of inhibitors of Helicobacter pylori glutamate racemase as selective antibacterial agents: incorporation of imidazoles onto a core pyrazolopyrimidinedione scaffold to improve bioavailabilty. Bioorg. Med. Chem. Lett., 2012, 22(17), 5600-5607.
109. Prado-Prado, F.J.; Uriarte, E.; Borges, F.; González-Díaz, H. Multi-target spectral moments for QSAR and Complex Networks study of antibacterial drugs. Eur. J. Med. Chem., 2009, 44(11), 4516-4521.
110. Roy, K.; Mandal, A.S. Development of linear and nonlinear predictive QSAR models and their external validation using molecular similarity principle for anti-HIV indolyl aryl sulfones. J. Enzy. Inhib. Med. Chem., 2008, 23(6), 980-995.
111. Marrero-Ponce, Y.; Medina-Marrero, R.; Torrens, F.; Martinez, Y.; Romero-Zaldivar, V.; Castro, E.A. Atom, atom-type, and total nonstochastic and stochastic quadratic fingerprints: a promising approach for modeling of antibacterial activity. Bioorg. Med. Chem., 2005, 13(8), 2881-2899.
112. Murcia-Soler, M.; Pérez-Giménez, F.; Garcia-March, F.J.; Salabert-Salvador, M.T.; Diaz-Villanueva, W.; Medina-Casamayor, P. Discrimination and selection of new potential antibacterial compounds using simple topological descriptors. J. Mol. Graph. Model, 2003, 21(5), 375-390.
113. Bush, K. Antimicrobial agents. Curr. Opin. Chem. Biol, 1997, 1(2), 169-175.
114. Galvez, J.; Garcia-Domenech, R.; de Julian-Ortiz, J. Assigning wave functions to graphs: A way to introduce novel topological indices. Commun. Mathem. Comp. Chem./MATCH, 2006, 56(3), 509-518.
115. González - Díaz, H.; Pérez - castillo, Y.; Podda, G.; Uriarte, E. Computational chemistry comparison of stable/nonstable protein mutants classification models based on 3D and topological indices. J. Comput. Chem., 2007, 28(12), 1990-1995.
116. González-Díaz, H.; Torres-Gómez, L.A.; Guevara, Y.; Almeida, M.S.; Molina, R.; Castañedo, N.; Santana, L.; Uriarte, E. Markovian chemicals "in silico" design (MARCH-INSIDE), a promising approach for computer-aided molecular design III: 2.5 D indices for the discovery of antibacterials. J. Mol. Model, 2005, 11(2), 116-123.
117. Du, Q.R.; Li, D.D.; Pi, Y.Z.; Li, J.R.; Sun, J.; Fang, F.; Zhong, W.Q.; Gong, H.B.; Zhu, H.L. Novel 1,3,4-oxadiazole thioether derivatives targeting thymidylate synthase as dual anticancer/antimicrobial agents. Bioorg. Med. Chem., 2013, 21(8), 2286-2297.